Immuno-Oncology
Immune cells have the capability to eliminate tumor cells; however, tumor cells can develop the ability to evade immune responses. Current research efforts have been focused on developing personalized strategies for cancer treatment and developing new therapies that bolster the immune response in the fight against tumor cells.
Below is a collection of scientific resources for your immuno-oncology research.
Featured
Production of Chimeric Antigen Receptor T Cells
This free Nature Protocols Wallchart summarizes the processes involved in producing CAR T cells for therapy.
Get Your Free Copy >-
Improving Cell Recovery with EasySep™ Negative Selection KitsTechnical tip from our dedicated team of Product and Scientific Support specialists -
Bhushan Dharmadhikari, PhDDr. Bhushan Dharmadhikari shares his work studying dendritic cells and their applications in cancer immunology and immunotherapy -
Sara McKee, PhDDr. Sara McKee discusses her research on antibody-based immunotherapy for B cell lymphoma -
Isolating Cells from Atypical SamplesTechnical tip from our dedicated team of Product and Scientific Support specialists -
Preparing a Polymorphonuclear Cell Fraction from Whole Blood using Ammonium Chloride LysisTechnical tip from our dedicated team of Product and Scientific Support specialists -
Reducing Platelet Contamination in Blood SamplesPlatelets (thrombocytes), cell fragments derived from megakaryocytes, are used in normal blood clotting, and must be handled gently to prevent activation -
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung CancerIn this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.<br><br>This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. <a href="/translational-t-cell-talks-2024">View the rest of the talks and read the Q&A transcripts.</a> -
Isolate Virtually Any Cell Type Using EasySep™ or EasySep™ Release Indirect Selection KitsUse any biotinylated, FITC-, PE- or APC-conjugated antibody to label your desired cells and mix with EasySep™ reagents to obtain highly purified cells
